OTCMKTS:ALPMY - ASTELLAS PHARMA/ADR Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$14.9750 +0.26 (+1.80 %)
(As of 11/19/2018 04:00 PM ET)
Previous Close$14.71
Today's Range$14.96 - $15.17
52-Week Range$12.34 - $17.99
Volume47,127 shs
Average Volume87,289 shs
Market Capitalization$29.13 billion
P/E Ratio18.62
Dividend Yield0.80%
Beta0.48
Astellas Pharma Inc., a pharmaceutical company, manufactures, markets, and imports and exports pharmaceutical products worldwide. The company offers Prograf and Advagraf/Graceptor/ASTAGRAF XL/Prograf XL, an immunosuppressant used to suppress organ transplant rejection; Vesicare, a treatment for overactive bladder; Harnal/Omnic, a blocking agent to treat the functional symptoms of benign prostatic hyperplasia; and Funguard/MYCAMIN, a candin-type antifungal agent. It also provides Geninax, an oral new-type quinolone antibacterial agent; Celecox, an anti-inflammatory agent; Lipitor, a treatment for hypercholesterolemia; Micardis/Micombi/Micamlo, a treatment for hypertension; Gaster, a treatment for peptic ulcer and gastritis; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic agonist indicated for the treatment of overactive bladder; Eligard, a luteinizing hormone-releasing hormone agonist for the treatment of prostate cancer; XTANDI for the treatment of prostate cancer; and VESOMNI, a release tablet for the treatment of moderate to severe storage symptoms and voiding symptoms associated with benign prostatic hyperplasia in men who are not adequately responding to treatment with monotherapy. In addition, the company offers Symbicort for the treatment for adult bronchial asthma and chronic obstructive pulmonary disease; Bonoteo for the treatment for osteoporosis; Suglat for the treatment of type 2 diabetes; and Repatha for the treatment of hypercholesterolemia. Further, the company provides Lexiscan, a pharmacologic stress agent; Tarceva, a treatment for non-small cell lung cancer; CRESEMBA, a azole antifungal; and Dificlir, a novel treatment for CDI. Additionally, it is developing enzalutamide, gilteritinib, and degarelix for oncology indications. The company has a collaborative and license agreement with Proteostasis Therapeutics, Inc. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.

Receive ALPMY News and Ratings via Email

Sign-up to receive the latest news and ratings for ALPMY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:ALPMY
Previous Symbol
CUSIPN/A
Phone813-3244-3000

Debt

Debt-to-Equity Ratio0.04
Current Ratio1.93
Quick Ratio1.59

Price-To-Earnings

Trailing P/E Ratio18.62
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$12.00 billion
Price / Sales2.47
Cash Flow$1.0349 per share
Price / Cash14.47
Book Value$5.52 per share
Price / Book2.71

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$1.48 billion
Net Margins13.49%
Return on Equity13.46%
Return on Assets9.37%

Miscellaneous

Employees16,617
Outstanding Shares1,980,000,000
Market Cap$29.13 billion
OptionableNot Optionable

ASTELLAS PHARMA/ADR (OTCMKTS:ALPMY) Frequently Asked Questions

What is ASTELLAS PHARMA/ADR's stock symbol?

ASTELLAS PHARMA/ADR trades on the OTCMKTS under the ticker symbol "ALPMY."

When did ASTELLAS PHARMA/ADR's stock split? How did ASTELLAS PHARMA/ADR's stock split work?

ASTELLAS PHARMA/ADR's stock split on the morning of Wednesday, April 2nd 2014. The 5-4 split was announced on Friday, March 14th 2014. The newly created shares were distributed to shareholders after the closing bell on Tuesday, April 1st 2014. An investor that had 100 shares of ASTELLAS PHARMA/ADR stock prior to the split would have 125 shares after the split.

How were ASTELLAS PHARMA/ADR's earnings last quarter?

ASTELLAS PHARMA/ADR (OTCMKTS:ALPMY) posted its quarterly earnings results on Wednesday, April, 25th. The company reported $0.10 EPS for the quarter, missing the Thomson Reuters' consensus estimate of $0.15 by $0.05. The business had revenue of $2.78 billion for the quarter. ASTELLAS PHARMA/ADR had a net margin of 13.49% and a return on equity of 13.46%. View ASTELLAS PHARMA/ADR's Earnings History.

When is ASTELLAS PHARMA/ADR's next earnings date?

ASTELLAS PHARMA/ADR is scheduled to release their next quarterly earnings announcement on Tuesday, November 20th 2018. View Earnings Estimates for ASTELLAS PHARMA/ADR.

What is the consensus analysts' recommendation for ASTELLAS PHARMA/ADR?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ASTELLAS PHARMA/ADR in the last year. There are currently 1 sell rating and 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for ASTELLAS PHARMA/ADR.

Has ASTELLAS PHARMA/ADR been receiving favorable news coverage?

Headlines about ALPMY stock have been trending somewhat positive recently, InfoTrie reports. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. ASTELLAS PHARMA/ADR earned a coverage optimism score of 0.9 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 9.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the next several days.

Who are some of ASTELLAS PHARMA/ADR's key competitors?

Who are ASTELLAS PHARMA/ADR's key executives?

ASTELLAS PHARMA/ADR's management team includes the folowing people:
  • Mr. Kenji Yasukawa Ph.D., Pres, CEO & Director (Age 58)
  • Mr. Chikashi Takeda, CFO & Sr. Corp. Exec.
  • Mr. Fumiaki Sakurai, Chief Admin. Officer, Chief Ethics & Compliance Officer and Corp. Exec.
  • Ms. Linda Friedman J.D., Gen. Counsel & VP
  • Mr. Jeffrey A. Winton, Chief Communications Officer and Sr. VP of Corp. Affairs (Age 60)

How do I buy shares of ASTELLAS PHARMA/ADR?

Shares of ALPMY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ASTELLAS PHARMA/ADR's stock price today?

One share of ALPMY stock can currently be purchased for approximately $14.9750.

How big of a company is ASTELLAS PHARMA/ADR?

ASTELLAS PHARMA/ADR has a market capitalization of $29.13 billion and generates $12.00 billion in revenue each year. ASTELLAS PHARMA/ADR employs 16,617 workers across the globe.

What is ASTELLAS PHARMA/ADR's official website?

The official website for ASTELLAS PHARMA/ADR is http://www.astellas.com.

How can I contact ASTELLAS PHARMA/ADR?

ASTELLAS PHARMA/ADR's mailing address is 2-5-1 Nihonbashi-Honcho Chuo-Ku, Tokyo M0, 103-8411. The company can be reached via phone at 813-3244-3000.


MarketBeat Community Rating for ASTELLAS PHARMA/ADR (OTCMKTS ALPMY)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  145 (Vote Outperform)
Underperform Votes:  99 (Vote Underperform)
Total Votes:  244
MarketBeat's community ratings are surveys of what our community members think about ASTELLAS PHARMA/ADR and other stocks. Vote "Outperform" if you believe ALPMY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALPMY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel